antibody production

For this article, we spoke with Vera Dreyfuss of evitria AG, an antibody expression services provider based in Switzerland, about the role that the NGC Chromatography System has played in powering the growth and success of the company.

Research into human diseases has led to the development of novel monoclonal antibody drugs. These monoclonal antibody therapies have been successful because of their specificity and selectivity. However, ongoing development and successfully launching a new mAb drug require robust and reliable methods to screen for drug targets, demonstrate drug safety and efficacy, and scale up manufacturing to meet the stringent regulatory guidelines required for approval.

Presented by: Katie Schaefer, PhD, Global Product Manager, Bio-Rad
Peter Winship, PhD, Technical Product Manager, Teledyne Cetac Technologies

View on demand

Purification is a multistep process toward confirmation of a target protein’s purity. In this webinar you will learn how to automate your protein purification workflow by following the creation of a hypothetical monoclonal antibody (mAb). Dr. Schaefer and Dr. Winship expertly demonstrate how the NGC Chromatography System and the AEX-500 series Autosampler work together to maximize screening capability as well as rapidly achieve therapeutic development objectives.

As phase 3 clinical trials of investigational vaccines for COVID-19 begin in the U.S., you may be wondering what it takes to make an effective vaccine? In case you missed it, check out our Hanging with My Chromies podcast, episodes 6 and 10 on vaccine development and viral spread, and learn about the role chromatography plays in making a successful vaccine.

See how an antibody expression service provider, Evitria (Zurich, Switzerland) optimized and expanded their antibody production services using the NGC Chromatography Systems to meet the growing demands of their customers.